Compare NCTY & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCTY | LONA |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | China | United States |
| Employees | N/A | 19 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.2M | 90.4M |
| IPO Year | 2004 | N/A |
| Metric | NCTY | LONA |
|---|---|---|
| Price | $5.20 | $9.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 28.3K | ★ 35.8K |
| Earning Date | 03-27-2015 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $4.21 |
| 52 Week High | $11.60 | $14.21 |
| Indicator | NCTY | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 42.84 | 49.10 |
| Support Level | $5.05 | $8.10 |
| Resistance Level | $5.91 | $9.88 |
| Average True Range (ATR) | 0.39 | 1.04 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 6.63 | 38.48 |
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Online game services, out of which Crypto mining business derives maximum revenue.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.